Premium
Fibroblast dynamics as an in vitro screening platform for anti‐fibrotic drugs in primary myelofibrosis
Author(s) -
Tomuleasa Ciprian,
Selicean Sonia,
Gafencu Grigore,
Petrushev Bobe,
Pop Laura,
Berce Cristian,
Jurj Anca,
Trifa Adrian,
Rosu AnaMaria,
Pasca Sergiu,
Magdo Lorand,
Zdrenghea Mihnea,
Dima Delia,
Tanase Alina,
Frinc Ioana,
Bojan Anca,
BerindanNeagoe Ioana,
Ghiaur Gabriel,
Ciurea Stefan O.
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.25902
Subject(s) - myelofibrosis , fibroblast , medicine , fibrosis , bone marrow , cancer research , clone (java method) , in vitro , immunology , pathology , biology , dna , biochemistry , genetics
Although the cause for bone marrow fibrosis in patients with myelofibrosis remains controversial, it has been hypothesized that it is caused by extensive fibroblast proliferation under the influence of cytokines generated by the malignant megakaryocytes. Moreover, there is no known drug therapy which could reverse the process. We studied the fibroblasts in a novel system using the hanging drop method, evaluated whether the fibroblasts obtain from patients are part of the malignant clone of not and, using this system, we screen a large library of FDA‐approved drugs to identify potential drugs candidates that might be useful in the treatment of this disease, specifically which would inhibit fibroblast proliferation and the development of bone marrow fibrosis. We have found that the BM fibroblasts are not part of the malignant clone, as previously suspected and two immunosuppressive medications—cyclosporine and mycophenolate mophetil, as most potent suppressors of the fibroblast collagen production thus potentially inhibitors of bone marrow fibrosis production in myelofibrosis.